The cumulative incidence of VTE among patients with ALK-positive NSCLC (95% CI) at index (representing the prior 6 months) and 6-, 12-, 24-, and 60-months post-index were 5% (3.7%-6.6%), 17.7% (13.9%-22.7%), 22.6% (17.7%-29.7%), 27.5% (21.2%-35.7%), and 32.8% (26.3%-41.4%), respectively (Fig. 1). Here, ALK is linked to non-small cell lung carcinoma.